EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudie

Prevalence of Germline Pathogenic RET Variants in a Pan-Cancer Patient Population

Matilde Borio iD, Margaret Sheehan, Nora Katabi, Rosalba E Sacca, Anna Maio, Yelena Kemel iD, Aliya Khurram, Diana Mandelker iD, Ozge Birsoy, David Solit iD, Maria I Carlo iD, Ying Liu iD und 11 weitere

JCO Precision Oncology · 2026-05 · 10 (5)

DOI: 10.1200/po-25-00737 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift JCO Precision Oncology, 2026-05. Verfasst von Matilde Borio und 22 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY. Hauptthemen laut MEDLINE: Carcinoma, Neuroendocrine, Germ-Line Mutation, Proto-Oncogene Proteins c-ret, Thyroid Neoplasms. Die Arbeit nennt 20 Literaturangaben. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Germline likely pathogenic or pathogenic variants (LP/PV) in the RET proto-oncogene account for approximately 25% of medullary thyroid cancers (MTCs). Depending on the variant, individuals with RET LP/PV can have > 70% lifetime risk for MTC or C-cell hyperplasia, an MTC precursor. We assessed prevalence and genotype-phenotype correlations of RET LP/PV in a pan-cancer population undergoing agnostic multigene germline cancer genetic testing. METHODS Patients with cancer at Memorial Sloan Kettering Cancer Center provided informed consent to Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets, a paired tumor-normal genomic sequencing protocol (ClinicalTrials.gov identifier: NCT01775072 ) from 2015 to 2023. Consent included multigene germline testing inclusive of RET . LP/PVs in RET were categorized per standardized MTC risk levels. Clinical data, including family history, surveillance results, and pathology, were extracted from medical records. RESULTS Twenty-one of 31,866 patients harbored an LP/PV in the RET gene, with the most common variant being p.Val804Met (n = 10) of moderate risk. Although six patients had a personal history of MTC, 15 of 21 patients (71%) had neither a personal nor a family history of MTC. Of the 15, nine underwent endocrinology high-risk surveillance, with five patients deciding to proceed with thyroidectomy due to abnormal surveillance findings. Pathologic findings consisted of isolated C-cell hyperplasia only (n = 1), microMTC and C-cell hyperplasia (n = 2), stage I MTC and C-cell hyperplasia (n = 1), and stage IVA MTC (n = 1). CONCLUSION In this pan-cancer cohort, 71% of RET LP/PV findings were incidental, with no prior personal or family history of MTC. High-risk surveillance and potential thyroidectomy are warranted in patients with an incidental germline RET LP/PV finding due to high rates of precursor lesions and MTC even among these patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, NeuroendocrineGerm-Line MutationProto-Oncogene Proteins c-retThyroid NeoplasmsAdultAgedFemaleHumansMaleMiddle AgedPrevalenceProto-Oncogene Mas

Substanzen

MAS1 protein, humanProto-Oncogene MasProto-Oncogene Proteins c-retRET protein, human

Autor:innen und Institutionen

  • Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.
  • Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.
  • Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY.
  • Weill Cornell Medical College, New York, NY.
  • Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY.
  • Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY.

ORCID-Profile: Matilde Borio, Yelena Kemel, Diana Mandelker, David Solit, Maria I Carlo, Ying Liu, Lauren Banaszak, Yonina R Murciano-Goroff, Alicia Latham, Kenneth Offit, Ronald Ghossein, Laura Boucai, Zsofia K Stadler

Förderung

  • NCI NIH HHS

Zitieren

APA

Borio, M., Sheehan, M., Katabi, N., Sacca, R. E., Maio, A., Kemel, Y., Khurram, A., Mandelker, D., Birsoy, O., Solit, D., Carlo, M. I., Liu, Y., Abbass, M., Banaszak, L., Kesserwan, C., Murciano-Goroff, Y. R., Latham, A., Offit, K., Wong, R. J., …, & Stadler, Z. K. (2026). Prevalence of Germline Pathogenic RET Variants in a Pan-Cancer Patient Population. JCO Precision Oncology, 10(5). https://doi.org/10.1200/po-25-00737

Vancouver

Borio M, Sheehan M, Katabi N, Sacca RE, Maio A, Kemel Y, et al. Prevalence of Germline Pathogenic RET Variants in a Pan-Cancer Patient Population. JCO Precision Oncology. 2026;10(5). doi:10.1200/po-25-00737

BibTeX
@article{Borio2026,
  author = {Borio, Matilde and Sheehan, Margaret and Katabi, Nora and Sacca, Rosalba E and Maio, Anna and Kemel, Yelena and Khurram, Aliya and Mandelker, Diana and Birsoy, Ozge and Solit, David and Carlo, Maria I and Liu, Ying and Abbass, Mohammad and Banaszak, Lauren and Kesserwan, Chimene and Murciano-Goroff, Yonina R and Latham, Alicia and Offit, Kenneth and Wong, Richard J and Ghossein, Ronald and Boucai, Laura and Tuttle, Michael and Stadler, Zsofia K},
  title = {Prevalence of Germline Pathogenic RET Variants in a Pan-Cancer Patient Population},
  journal = {JCO Precision Oncology},
  year = {2026},
  volume = {10},
  number = {5},
  doi = {10.1200/po-25-00737}
}
Kostenlos starten →